Your browser doesn't support javascript.
loading
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate.
Sliepen, Kwinten; Radic, Laura; Capella-Pujol, Joan; Watanabe, Yasunori; Zon, Ian; Chumbe, Ana; Lee, Wen-Hsin; de Gast, Marlon; Koopsen, Jelle; Koekkoek, Sylvie; Del Moral-Sánchez, Iván; Brouwer, Philip J M; Ravichandran, Rashmi; Ozorowski, Gabriel; King, Neil P; Ward, Andrew B; van Gils, Marit J; Crispin, Max; Schinkel, Janke; Sanders, Rogier W.
Afiliação
  • Sliepen K; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands. k.h.sliepen@amsterdamumc.nl.
  • Radic L; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands. k.h.sliepen@amsterdamumc.nl.
  • Capella-Pujol J; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Watanabe Y; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • Zon I; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Chumbe A; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • Lee WH; School of Biological Sciences, University of Southampton, Southampton, UK.
  • de Gast M; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Koopsen J; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • Koekkoek S; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Del Moral-Sánchez I; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • Brouwer PJM; Department of Structural Biology and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Ravichandran R; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Ozorowski G; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • King NP; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Ward AB; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • van Gils MJ; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Crispin M; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
  • Schinkel J; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
  • Sanders RW; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands.
Nat Commun ; 13(1): 7271, 2022 11 25.
Article em En | MEDLINE | ID: mdl-36434005
ABSTRACT
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes ~300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly sequence diverse E1E2 glycoprotein. Eliciting broadly neutralizing antibodies that recognize conserved cross-neutralizing epitopes is important for an effective HCV vaccine. However, most recombinant HCV glycoprotein vaccines, which usually include only E2, induce only weak neutralizing antibody responses. Here, we describe recombinant soluble E1E2 immunogens that were generated by permutation of the E1 and E2 subunits. We displayed the E2E1 immunogens on two-component nanoparticles and these nanoparticles induce significantly more potent neutralizing antibody responses than E2. Next, we generated mosaic nanoparticles co-displaying six different E2E1 immunogens. These mosaic E2E1 nanoparticles elicit significantly improved neutralization compared to monovalent E2E1 nanoparticles. These results provide a roadmap for the generation of an HCV vaccine that induces potent and broad neutralization.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Hepatite C / Nanopartículas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Hepatite C / Nanopartículas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article